<DOC>
	<DOCNO>NCT00551577</DOCNO>
	<brief_summary>The purpose study evaluate response neoadjuvant chemotherapy image observation anatomical biological indicator ( i.e . ascites continuous measurement tumor marker CA 125 ) . Furthermore optimal number preoperative administered cycle combination chemotherapy carboplatin docetaxel determine .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Carboplatin Docetaxel Patients With Advanced Ovarian Cancer-Prospective , Randomized Phase II Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histological confirm ovarian neoplasm Figo stage IIIC ( 2cm extrapelvic disease ) Figo IV 500 ml ascites volume ( measured sonography ) age &gt; 18 year old ECOG &lt; = 2 adequate hepatological , renal haematological function inform consent concomitant previous malignant disease debulking procedure initial surgical approach exist peripheral sensoric neuropathy &gt; = grade 2 acute infection mental disorder , cerebral metastasis bowel obstruction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Ovarian neoplasm ,</keyword>
	<keyword>Neoadjuvant Therapy ,</keyword>
	<keyword>Docetaxel ,</keyword>
	<keyword>Neoplasm , Residual</keyword>
</DOC>